Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)
Background Several dual bronchodilator combinations of long‐acting beta 2‐agonist (LABA)
and long‐acting muscarinic antagonist (LAMA) have been approved for treatment of stable …
and long‐acting muscarinic antagonist (LAMA) have been approved for treatment of stable …
The airways' mechanical stress in lung disease: implications for COPD pathophysiology and treatment evaluation
P Santus, M Pecchiari, F Tursi, V Valenti… - Canadian …, 2019 - Wiley Online Library
The airway epithelium stretches and relaxes during the normal respiratory cycle, and
hyperventilation exaggerates this effect, resulting in changes in lung physiology. In fact …
hyperventilation exaggerates this effect, resulting in changes in lung physiology. In fact …
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized …
GT Ferguson, N Brown, C Compton, TC Corbridge… - Respiratory …, 2020 - Springer
Background The comparative efficacy of inhaled corticosteroid/long-acting muscarinic
antagonist/long-acting β 2-agonist (ICS/LAMA/LABA) triple therapy administered via single …
antagonist/long-acting β 2-agonist (ICS/LAMA/LABA) triple therapy administered via single …
Recombinant club cell protein 16 (CC16) ameliorates cigarette smoke‑induced lung inflammation in a murine disease model of COPD
M Pang, HY Liu, T Li, D Wang… - Molecular …, 2018 - spandidos-publications.com
Club cell protein (CC16) is expressed primarily by club cells possesses anti‑inflammatory
properties and is located in the bronchiolar epithelium. Previous studies have demonstrated …
properties and is located in the bronchiolar epithelium. Previous studies have demonstrated …
High 24-hour respiratory symptoms and low physical activity in the stable copd romanian cohort of space study
F Mihaltan, RM Rajnoveanu, OC Arghir… - … Journal of Chronic …, 2021 - Taylor & Francis
Objective This study assessed the characteristics and the relationship between symptoms in
any part of the 24-hour (24-h) day, physical activity level (PAL), and other clinical and …
any part of the 24-hour (24-h) day, physical activity level (PAL), and other clinical and …
Cost-effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment
M Capel, M Mareque, CJ Álvarez, L Lindner… - Clinical Drug …, 2018 - Springer
Abstract Background and Objective Chronic obstructive pulmonary disease (COPD), a
progressive lung disorder associated with decline of respiratory function, affects 10.2% of …
progressive lung disorder associated with decline of respiratory function, affects 10.2% of …
Основные фенотипы хронической обструктивной болезни легких
ЛВ Куколь, ЛИ Арчакова, ЕР Молокова - Медицинский альянс, 2019 - med-alyans.ru
Аннотация Хроническая обструктивная болезнь легких (ХОБЛ) является одной из
основных причин мировой заболеваемости и смертности с тенденцией к росту …
основных причин мировой заболеваемости и смертности с тенденцией к росту …
[HTML][HTML] Bronchodilator therapy in patients with chronic obstructive pulmonary disease: what should be considered in clinical practice when choosing a dosing …
ON Titova, NA Kuzubova, AG Kozyrev… - …, 2023 - journal.pulmonology.ru
The use of long-acting bronchodilators is central to the chronic obstructive pulmonary
disease (COPD) therapy. One of the goals of bronchodilation is to reduce the morning …
disease (COPD) therapy. One of the goals of bronchodilation is to reduce the morning …
Бронхолитическая терапия при хронической обструктивной болезни легких: что следует учитывать в клинической практике при выборе режима дозирования …
ОН Титова, НА Кузубова, АГ Козырев… - …, 2023 - journal.pulmonology.ru
Аннотация Применение бронхолитических препаратов длительного действия (ДД)
составляет основу лечения хронической обструктивной болезни легких (ХОБЛ). Одной …
составляет основу лечения хронической обструктивной болезни легких (ХОБЛ). Одной …
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
AD D'Urzo, D Singh, JF Donohue… - … journal of chronic …, 2019 - Taylor & Francis
Background Aclidinium/formoterol 400/12 µg is a twice-daily maintenance bronchodilator for
COPD. This post hoc study evaluated aclidinium/formoterol vs aclidinium 400 µg, formoterol …
COPD. This post hoc study evaluated aclidinium/formoterol vs aclidinium 400 µg, formoterol …